Trial Profile
Phase I/II Study of CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 12 May 2017 New trial record